You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Risk Factors of H. pylori Infection2

Guidelines & recommendations:

Guidelines recommending triple Drug therapy and Quadruple therapy including Amoxycillin for the treatment of Helicobacter pylori infections: 

Journal of Global antimicrobial
Resistance 2018

The American Journal of
Gastroenterology 2017

Centers for Disease Control and Prevention 20178

TOP* Guidelines by Alberta
Medical Association 20164

Choose Amoxil (Amoxycillin) to treat
Helicobacter pylori induced infections, because

Amoxil is rapidly bactericidal and possesses the safety profile of a penicillin5

H.pylori develops 0% resistance to Amoxycillin6

Recommended therapy for Helicobacter pylori
eradication in peptic Ulcer Patients

Dosage for Adults Triple Therapy Treatment5
Two Amoxycillin Capsules 500 mg BID
Omeprazole 20 mg BID
Clarithromycin 500 mg BID or
Metronidazole 500 mg


  1. Pastukh, et al., Antimicrobial susceptibility of H. pylori strains isolated from   children in Israel, Journal of Global Antimicrobial Resistance 12, ELSEVIER (2018) 175–178.
  2. Mhaskar RS, Ricardo I, Azliyati A, et al. Assessment of risk factors of helicobacter pylori infection and peptic ulcer disease. J Glob Infect Dis. 2013;5(2):60-67.  doi:10.4103/0974-777X.112288. DOI: 10.4103/0974-777X.112288.
  3. William D. Chey, et al., ACG Clinical Guideline: Treatment of H. pylori Infection, Am J Gastroenterol 2017; 112:212–238.
  4. TOP Guidelines by Alberta Medical Association 2016 DIAGNOSIS AND TREATMENT OF H. pylori INFECTION IN ADULTS Clinical Practice Guideline | June 2016.
  5. Amoxil Datasheet. Version number:GDS31/IPI13. Date of issue: 13 June 2019.
  6. Tan B., et al., Helicobacter pylori Antimicrobial Susceptibility Testing Guided Salvage Therapy in the USA: A Real-Life Experience, Digestive Diseases and Sciences  (2018) 63:437–445.
  7. Amoxil Datasheet. Version no. GDS31/IPI13. Dated: 13th June 2019.
  8. Center for Disease Control and Prevention: last updated: June 12, 2017.

Adverse Events must be reported. For products related to GSK Pakistan, please report adverse events via email at or call us at +92 (21) 111 475 725 - Ext: 7 & 8

Full prescribing information is available on request.
GlaxoSmithKline Pakistan Limited
35 - Dockyard Road, West Wharf, Karachi - 74000.
Amoxil is a trademark of GlaxoSmithKline group of companies. 
GlaxoSmithKline Pakistan Limited is a member of GlaxoSmithKline group of companies.
© 2021 GlaxoSmithKline Pakistan Limited.